StreetAlpha.app
Home › Stocks › BNTX

BioNTech SE (BNTX)

Healthcare
$84.86
▼ −0.47%
LAST CLOSE · NOV 17

BioNTech develops immunotherapies for cancer and infectious diseases and sells the COVID-19 vaccine Comirnaty. It last closed at $84.86 on Nov 17, down 0.47% on the day. The average 12-month price target from 7 analysts is $116.14 (+36.9% from the last close), with a high of $132.00 and a low of $105.00. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (6 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in BNTX, 50% of them bullish and 50% bearish. In the past 30 days there were 2 dark pool prints totaling $1.8M, the largest $937K.

AI Auto Pilots
Is BNTX in one of our four AI portfolios? Sign in free to see

Key Stats

Fiscal 2025
Results
Revenue
EUR 2.9B
+4.3% vs a year ago
Net income
−EUR 1.1B
−39.6% margin
Free cash flow
EUR 280.9M
9.8% margin
Operating margin
−49.0%
−EUR 1.4B operating income
Balance sheet
Cash & equivalents
EUR 7.7B
At Dec 31
Shareholder equity
EUR 19.2B
CEOUğur Şahin
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: EUR 19.0BEUR 19.0BFY2021FY2022: EUR 17.3BEUR 17.3BFY2022FY2023: EUR 3.8BEUR 3.8BFY2023FY2024: EUR 2.8BEUR 2.8BFY2024FY2025: EUR 2.9BEUR 2.9BFY2025

From BNTX's SEC filings, latest 20-F/A for the period ending Dec 31, 2025 (filed Jul 30). Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 7 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
7firms
6 Buy1 Hold0 Sell
Each firm's latest rating on BNTX in the past 90 days
Average 12-month target
$116.14
▲ 36.9% upside

Based on 7 analysts who set a price target on BNTX in the past 90 days. The average target is $116.14, with a high of $132.00 and a low of $105.00, compared with the last close of $84.86.

Low $105.00Avg $116.14High $132.00
Blue marker: last close $84.86
Highest target$132.00
Average target$116.14
Lowest target$105.00
Latest rating changes
HC Wainwright & Co.Maintained
Nov 9Buy$110
UBSTarget lowered
Nov 4Buy$135 → $125
Morgan StanleyTarget lowered
Nov 4Buy$114 → $106
Wells FargoMaintained
Nov 4Buy$125
Evercore ISI GroupTarget lowered
Nov 4Buy$130 → $110
DateFirmActionRatingPrice target
Nov 9HC Wainwright & Co.MaintainedBuy$110
Nov 4UBSTarget loweredBuy$135 → $125
Nov 4Morgan StanleyTarget loweredBuy$114 → $106
Nov 4Wells FargoMaintainedBuy$125
Nov 4Evercore ISI GroupTarget loweredBuy$130 → $110
Loading…

Technical Analysis

BNTX · as of the Nov 17 close · updated after every close
Downtrend

The stock is 3% below its 20 day and 9% below its 50 day average. It is 13% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 39). The nearest support is the Pivot S1 at $84.32, and the nearest resistance the Pivot at $84.92.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 3.1%/day
Key levels
$124.0052 week high+46.1%
$95.48200 day average+12.5%
$94.54100 day average+11.4%
$92.4350 day average+8.9%
$91.46Swing high (Nov 4)+7.8%
$87.5020 day average+3.1%
$85.47Pivot R1+0.7%
$84.92Pivot+0.1%
$84.86Last close
$84.32Pivot S1−0.6%
$79.5252 week low−6.3%
Indicators
RSI (14)38.88Weak, oversold below 30Neutral
MACD-1.97Above its signal lineBullish
Stochastic14.6Near the bottom of its rangeOversold
ADX (14)15.5No clear trend
Williams %R-90.7Oversold below −80, overbought above −20Oversold
CCI (20)-141.4Oversold below −100, overbought above 100Oversold
Rate of change−2.4%Change over 10 sessionsBearish
ATR (14)$2.61Typical daily range, 3.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BNTX

What happened before

See how BNTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow BNTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How BNTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
2
Bullish
1
50%
Bearish
1
50%
Date span
Oct 29 – Nov 3
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$1.8M
Largest print
$937K
Loading…

BNTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲145 buying vs 126 selling
  • ●Shares held by funds -0.2%
  • ▲Funds holding +18
  • ▲Superinvestors: 3 added, 1 cut
  • ▲Put/call 1.05 to 0.20
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding302284+6.3%
In funds' top 10550.0%
Held by funds–––
New / increased56 / 8939 / 92+10.7%
Reduced / sold out89 / 3771 / 30+24.8%
Put/call ratio0.201.05−80.7%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BNTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BNTX is in one of them and how their past BNTX trades turned out.

BNTX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BNTX in an article yet. Here's the latest on the wider market.

BNTX Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Sep 12
Who traded BNTX · since 2022
Latest 5 filings of 9
$1K – $15KTraded Aug 7, 2025Filed Sep 12, 2025
$1K – $15KTraded Sep 3, 2024Filed Oct 3, 2024
Josh GottheimerSell (partial)
$1K – $15KTraded Aug 30, 2024Filed Sep 11, 2024
$1K – $15KTraded Apr 15, 2024Filed May 15, 2024
$1K – $15KTraded Mar 14, 2024Filed Apr 7, 2024
PersonTypeAmountTradedFiledDelay
Valerie HoyleD · ORSell$1K – $15KAug 7, 2025Sep 12, 202536 d
Josh GottheimerD · NJSell$1K – $15KSep 3, 2024Oct 3, 202430 d
Josh GottheimerD · NJSell (partial)$1K – $15KAug 30, 2024Sep 11, 202412 d
Josh GottheimerD · NJBuy$1K – $15KApr 15, 2024May 15, 202430 d
Josh GottheimerD · NJSell$1K – $15KMar 14, 2024Apr 7, 202424 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About BioNTech SE

BioNTech is a biotechnology company based in Mainz, Germany, that develops medicines based on the immune system. Its main focus is cancer, with further work on vaccines and therapies for infectious diseases, using messenger RNA and protein-based technologies. Its marketed product is Comirnaty, a COVID-19 vaccine sold through partners such as Pfizer and Fosun Pharma in many countries. Its customers are mainly public health authorities and healthcare systems that buy vaccines. Most of its other products are still being tested in clinical trials.

Headquarters
Mainz, Germany
Founded
2008